s6c-sarafotoxin and Cardiovascular-Diseases

s6c-sarafotoxin has been researched along with Cardiovascular-Diseases* in 2 studies

Reviews

1 review(s) available for s6c-sarafotoxin and Cardiovascular-Diseases

ArticleYear
The application of toxins and venoms to cardiovascular drug discovery.
    Current opinion in pharmacology, 2009, Volume: 9, Issue:2

    Animal venoms contain a variety of highly selective and potent toxins, which have evolved over thousands/millions of years, which target vital physiological processes. As such, they have proven to be an excellent source of lead compounds for the development of therapeutic agents. In particular, a number of these venom components (e.g. bradykinin-potentiating peptides, sarafotoxins, natriuretic peptides) have profound effects on the cardiovascular system. This review article examines recent progress in the search for lead compounds or novel scaffolds for cardiovascular drug development from animal venoms.

    Topics: Animals; Anti-Arrhythmia Agents; Cardiovascular Diseases; Drug Discovery; Humans; Incretins; Natriuretic Peptides; Oligopeptides; Toxins, Biological; Viper Venoms

2009

Other Studies

1 other study(ies) available for s6c-sarafotoxin and Cardiovascular-Diseases

ArticleYear
PKC and MAPK signalling pathways regulate vascular endothelin receptor expression.
    European journal of pharmacology, 2008, Feb-02, Volume: 580, Issue:1-2

    Up-regulation of vascular endothelin type A (ET(A)) and type B (ET(B)) receptors are implicated in the pathogenesis of cardiovascular disease. Culture of arteries has been shown to induce similar receptor alterations and has therefore been suggested as a suitable method for in detail delineation of the regulation of endothelin receptors. We hypothesize that protein kinase C (PKC) and mitogen-activated kinases (MAPK) are involved in the regulation of endothelin receptors. Porcine coronary arteries were studied before and after 24 h of culture, using in vitro pharmacology, real-time PCR and immunofluorescence techniques. Sarafotoxin 6c and endothelin ET-1 were used to examine the endothelin ET(A) and ET(B) receptor effects. The involvement of PKC and MAPK in the receptor regulation was examined by culture in the presence of antagonists. Organ culture resulted in increased sarafotoxin 6c and endothelin-1 contractions, endothelin ET(A) and ET(B) receptor immunofluorescence staining intensities and endothelin ET(B), but not ET(A), receptor mRNA levels. The general PKC inhibitors, bisindolylmaleimide I (10 microM) or Ro-32-0432 (10 microM), inhibited these effects. Also, the increase in sarafotoxin 6c contraction, endothelin ET(B) receptor and mRNA levels and endothelin ET(A) and ET(B) immunofluorescence staining intensities were inhibited by MAPK inhibitors for extracellular signal related kinases 1 and 2 (ERK1/2), PD98059 (10 microM), C-jun terminal kinase (JNK), SP600125 (10 microM), but not by p38 MAPK, SB203580 (10 microM). In conclusion, PKC and MAPK seem to be involved in the regulation of endothelin receptor expression in porcine coronary arteries. Inhibiting these intracellular signal transduction pathways may provide a future therapeutic target for hindering the development of vascular endothelin receptor changes in cardiovascular disease.

    Topics: Animals; Cardiovascular Diseases; Coronary Vessels; Endothelin-1; Female; Male; Mitogen-Activated Protein Kinases; Organ Culture Techniques; Protein Kinase C; Receptor, Endothelin A; Receptor, Endothelin B; RNA, Messenger; Signal Transduction; Swine; Up-Regulation; Viper Venoms

2008